Letter to Editor Volume 2 Issue 2
University of Qasim, Iraq
Correspondence: Ibrahim MSAW Shnawa, College of Biotechnology, University of Qasim, Qasim, Babylon, Iraq
Received: March 30, 2016 | Published: April 7, 2016
Citation: Shnawa IM (2016) Vaccine Allied Biologics. Int J Vaccines Vaccin 2(2): 00024. DOI: 10.15406/ijvv.2016.02.00024
One of the themes that are longly born in mind, those concerning “Vaccine versus Probiotics”. Then, if it is feasible to raise a question such as “Could we consider Probiotic as a vaccine, since they have an in-common indication, applications and/or attributes (Table 1). The common affairs are rather more than the different affairs. Thus, I think that they are forms of bio- therapeutics owning vaccine like potentials or one can say that they are vaccine-allied biologics.
Vaccines |
Probiotics |
Features |
|
Pathogens or their subunits |
Certain commensal bacteria |
Starter |
|
Specific in most cases |
Nonspecific in most cases |
Specificity |
|
Stringent for human favor |
Less stringent for human favor |
Evaluation attitude |
|
Needs special dispensing menu |
Drug-like dispensing menu |
Dispensing |
|
Specific mostly |
Nonspecific, mostly |
Specificity |
|
Immunoprphylaction |
Biotherapy of various immune defects |
Indication |
|
Massive use rather than individual cases |
On individual basis more than massive |
Use |
|
Infectious, epidemic and pandemic threat or |
Infectious and non-infectious |
Disease nature |
|
Based on affinity of B and T memory cells |
Bacteriocin, immunomodulatory, anticancerous |
Mode of action |
|
Mild short duration like fever and ill |
No appearent side effect |
Side Effect |
|
Due to vaccine or host born causes |
Due to probiotic or host born causes |
Failure |
Table 1 Characteristics of vaccine versus probiotics
None.
Author declares there are no conflicts of interest.
None.
©2016 Shnawa. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.